Cui Zhaolei, Li Yun, Gao Yanni, Kong Lingying, Lin Yingfeng, Chen Yan
Laboratory of Biochemistry and Molecular Biology Research, Fujian Provincial Key Laboratory of Tumor Biotherapy, Department of Clinical Laboratory, Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, Fuzhou 350014, Fujian, PR China.
Department of Blood Transfusion, The First Hospital of Fujian Medical University, Fuzhou 350009, Fujian, PR China.
Aging (Albany NY). 2020 Oct 9;12(19):19455-19467. doi: 10.18632/aging.103879.
Expressions and clinical implications of cancer-testis antigen (CTA) lactate dehydrogenase (LDH)-C4 in hepatocellular carcinoma (HCC) have not been fully elucidated. Herein, expressions of mRNA in the serum and serum-derived exosomes of early-stage HCC patients were determined using qRT-PCR, and the expression of LDH-C4 protein in HCC tissues was detected using high-throughput tissue microarray analysis. It was found that positive rates of mRNA expressions in the serum and serum exosomes of HCC patients were 68% and 60%, respectively. The AUCs of serum and exosomal in differentiating HCC patients from healthy controls were 0.8382 and 0.9451, respectively. The serum and exosomal levels in HCC patients in the treatment group were higher than the levels in the preliminary diagnosis group, but lower than those in the recurrence group. Survival analysis showed that the expression of LDH-C4 was negatively correlated with the prognosis of HCC. The Cox regression analysis showed that an LDH-C4 level was an independent risk factor for the prognosis of HCC patients. Therefore, serum and exosomal can be used as a biomarker for early diagnosis, efficacy evaluation and recurrence prediction of HCC. Moreover, LDH-C4 can be used as an important reference indicator for monitoring the prognosis of HCC.
癌胚抗原（CTA）乳酸脱氢酶（LDH）-C4在肝细胞癌（HCC）中的表达及其临床意义尚未完全阐明。在此，采用qRT-PCR检测早期HCC患者血清及血清来源外泌体中mRNA的表达，并通过高通量组织芯片分析检测HCC组织中LDH-C4蛋白的表达。结果发现，HCC患者血清和血清外泌体中mRNA表达的阳性率分别为68%和60%。血清和外泌体在区分HCC患者与健康对照中的AUC分别为0.8382和0.9451。治疗组HCC患者的血清和外泌体水平高于初诊组，但低于复发组。生存分析表明，LDH-C4的表达与HCC的预后呈负相关。Cox回归分析表明，LDH-C4水平是HCC患者预后的独立危险因素。因此，血清和外泌体可作为HCC早期诊断、疗效评估和复发预测的生物标志物。此外，LDH-C4可作为监测HCC预后的重要参考指标。
